Global health sector strategies on, respectively, HIV, viral hepatitis, and sexually transmitted infections for the period 2022-2030 guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS, viral hepatitis B and C and sexually transmitted infections by 2030. The 2022-2030 strategies recommend shared and disease-specific country actions supported by actions by the World Health Organization and partners. They consider the epidemiological, technological, and contextual shifts of recent years, foster learnings across the disease areas, and create opportunities to leverage innovations and new knowledge for effective responses to HIV, viral hepatitis, and sexually transmitted infections. The strategies call for a precise focus to reach the people most affected and at risk for each disease that addresses inequities. They promote synergies under a universal health coverage and primary health care framework and contribute to achieving the goals of the 2030 Agenda for Sustainable Development. The Seventy-Fifth World Health Assembly requested progress reports on the implementation of the strategies in 2024, 2026, 2028 and 2031, noting that the 2026 report will provide a mid-term review based on the progress made in meeting the strategies’ 2025 targets.

This report is the first of a series of biennial progress reports on the implementation of the Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. It draws attention to areas of progress and gaps in preparation for the mid-term review of the strategies in 2026.

This publication has been developed to provide a national framework for monitoring the health sector’s response to sexually transmitted infections and a set of core indicators to: -support countries monitor their programming for sexually transmitted infections and to identify gaps and challenges; and -facilitate regional and global tracking of the progress of WHO Member States in strengthening STI programming towards achieving the targets outlined in the global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections. The core indicators are structured around currently available STI interventions and data that are routinely collected or can be monitored at least annually. The indicators are aligned with global reporting requirements and to the targets detailed in the global health sector strategies. Collecting and analysing these data will provide a comprehensive picture of the health burden of STIs and will inform how best to allocate resources to improve the effectiveness, efficiency and equity of STI services. The publication also outlines a stepwise approach to strengthen the monitoring of STI programmes and STI surveillance.

This document presents a summary of the meeting held by Lusophone countries in March 2024 in Brasília, Brazil. The discussions focused on integrated responses to HIV, viral hepatitis, sexually transmitted infections, and tuberculosis. The objective was to strengthen country collaboration and exchange best practices to eradicate these infections as public health issues by 2030. This report outlines the common challenges, priorities, and opportunities to improve an integrated public health response to these diseases, addressing both healthcare systems and community-based interventions. The primary audience includes national health program managers, public health policymakers, clinicians, and healthcare providers. Furthermore, it will interest advisory boards, international agencies, and organizations that offer technical and financial support to health programs.

This technical brief provides practical information on integrating NCDs into the HIV service package and answers frequently asked questions on this subject to facilitate the integration. The target audiences are ministries of health, HIV and NCDs program managers, and relevant stakeholders involved in the planning and implementing HIV services

For the global community to be able to achieve ambitious targets relating to the prevention and treatment of HIV, viral hepatitis and sexually transmitted infections (STIs), multiple types of medicines must be widely accessible to all affected populations in all countries. The purpose of this report is to provide forecasts of future demand for medicines used in the fields of HIV, viral hepatitis and STIs. This report jointly presents medicines forecasts across three disease areas in recognition of the benefits of addressing HIV, viral hepatitis and STIs in a coordinated manner.

The purpose of this report is to provide forecasts of future demand for diagnostic tests used in the fields of HIV and viral hepatitis. These forecasts have multiple potential uses. First, they may inform advocacy efforts to increase access to diagnostics. Second, they may guide health systems and procurement organizations in planning how to obtain adequate supplies of diagnostics to fulfil service delivery needs. Third, they may aid manufacturers in identifying opportunities to contribute to meeting anticipated market demands. This report jointly presents diagnostic test forecasts across disease areas in recognition of the benefits of addressing HIV and viral hepatitis B and C in a coordinated manner.